Different subsets of tumor infiltrating lymphocytes correlate with NPC progression in different ways

Table 3 Association of the CD8⁺, Granzyme B⁺, Foxp3⁺ or IL17⁺ TIL number and clinicopathological characteristics in NPC patients

Characteristics	CD8 Positive			Granzyme B Positive			Foxp3 Positive			IL17 Positive
	≤52.50 (n = 53)	> 52.50 (n = 53)	P	≤32.45 (n = 53)	> 32.45 (n = 53)	P	≤74.00 (n = 53)	>74.00 (n = 53)	P	≤5.60 (n = 54)	>5.60 (n = 52)	P
Age, years
≤49	27	27		21	34		24	31		27	28
>49	26	25	0.846	32	19	0.011*	29	22	0.174	27	24	0.692
Gender
Male	41	43		41	43		39	44		42	42
Female	12	10	0.632	12	10	0.632	14	8	0.359	12	10	0.704
Tumor (T) stage
T1+T2	28	29		22	35		21	36		26	31
T3+T4	25	24	0.846	31	18	0.011*	32	17	0.003*	28	21	0.236
Lymphoid Nodal (N) status
N0	13	5		9	9		10	8		9	9
N1-3	40	48	0.038*	44	44	1.000	43	45	0.605	45	43	0.930
TNM Clinical stage
I+II	21	17		16	22		14	24		15	23
III+IVa+IVb	32	36	0.418	37	31	0.224	38	29	0.043*	39	29	0.077
LMP1
-	25	31		30	26		28	28		31	25
+	27	20	0.195	22	25	0.494	23	24	0.914	21	26	0.280